RxDoctor Payments Data

George Shokri

Neurology · Marietta, OHNPI 1851677074

Payments from drug & device makers

$22,224in general payments, 2019–2025

Across 790 payments — averaging $28.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$7K
  • Biohaven Pharmaceutical Holding Company Ltd.$3K
  • UCB, Inc.$1K
  • Biogen$1K
  • SK Life Science, Inc.$1K
  • Pfizer$776
  • plus $8K from 39 others

What the payments were for

  • Speaking & faculty fees$7,13632%
  • Food & beverage$14,92667%
  • Education$1631%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,224 in reported general payments places this provider in the 70th percentile of 702 neurology providers in Ohio.

See all neurology providers in Ohio

Medicare billing

Part B allowed, 2024
$134,183
Medicare patients
606
Services billed
1,700

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Radicava OrsEdaravone22$289,416
XcopriCenobamate103$117,110
UbrelvyUbrogepant69$96,661
BotoxOnabotulinumtoxina66$78,285
Aimovig AutoinjectorErenumab-Aooe94$69,699
QuliptaAtogepant55$68,460
NuplazidPimavanserin Tartrate15$62,176
Nurtec OdtRimegepant Sulfate53$58,556
EliquisApixaban74$50,851
BriviactBrivaracetam39$49,500
Repatha SureclickEvolocumab42$29,105
RytaryCarbidopa/Levodopa35$27,660
Ajovy AutoinjectorFremanezumab-Vfrm29$23,930
ZavzpretZavegepant Hcl15$16,594
Emgality PenGalcanezumab-Gnlm16$11,134

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Botox, Qulipta$6,878$243,406190 claims
PfizerNurtec Odt, Eliquis, Zavzpret$776$126,000142 claims
SK Life Science, Inc.Xcopri$1,226$117,110103 claims
Acadia Pharmaceuticals IncNuplazid$134$62,17615 claims
UCB, Inc.Briviact, Nayzilam$1,454$57,72751 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$127$28,94546 claims
Upsher-smith Laboratories LLCTopiramate$14$1,434121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 702 neurology providers in Ohio.

Other neurology in Marietta

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →